Webinars brought to you by Technology Networks

Webinars by Technology Networks 

Metabolic rewiring has long been overlooked as a significant pathogenic mechanism in cancer. My group’s work provides indubitable evidence that the reciprocal relationship between changes in metabolism and oncogenic signaling creates dependencies that promise future targets for clinical investigation.

This webinar will discuss the use of cutting-edge technologies, to track the metabolism of breast cancer tumors and preclinical models, for the identification of metabolic determinants that guide the response to anticancer therapies. In this context, it will assist with gaining insight into how the metabolism of a cancer cell, driven by oncogenic mutation in PIK3CA, affects its proliferation beyond a cell-autonomous manner and contributes to evading immune surveillance.

In the longer term, this knowledge exposes weaknesses in the tumor’s armor and unveils more effective therapeutic strategies where the combination of dietary interventions and metabolic targets helps circumvent drug resistance, restores tumoral immune cell infiltration and slows down tumor growth.

Attend this webinar to explore:

The use of cutting-edge technologies to track tumor metabolism
Crosstalk between oncogenic signaling and metabolic rewiring
The role of dietary interventions in anticancer therapy response

Harnessing the Metabolism of Oncogenic Signaling for More Effective Anticancer Therapy

Webinar Summary
T cells mediate the classic immune response to viral infections and appear to play these roles in fighting COVID-19 and clearing SARS-CoV-2. In addition to killing virally infected cells, T cells direct the production of high-affinity and neutralizing antibodies. In other viral illnesses, T-cell immunity provides long-term, durable protection and blocks forward transmission; protective immunity decreases the symptom severity of subsequent infection.

The goal of vaccination is to mimic the protective immunity from natural infection with lower risk. The mRNA Emergency Use Authorization (EUA) vaccines have shown high levels of protection against symptomatic COVID-19 for at least six months. The SARS-CoV-2 variants are concerning, and appear to evade antibody immunity, but perhaps not T-cell immunity. The prospect that T cell-directed vaccines may protect against variants has scientists racing to develop broadly protective vaccines ahead of the rapidly evolving mutants.

Attendees will learn how:

T cells (helper and killer) work in tandem to control and clear the ongoing infection
T cells recognize and eliminate SARS-CoV-2 infected cells
Vaccines can elicit T-cell immune responses

T-Cell Immunity and COVID-19

Many viruses are surrounded by lipid membranes, including SARS-CoV-2 and influenza. Both viruses contain viroporins, which are small, single pass transmembrane proteins that oligomerize to form ion channels. The influenza M2 viroporin is already a clinically approved antiviral drug target. In other coronaviruses, the E protein viroporin which is involved in growth, could be a potential target for COVID-19 vaccine and antiviral development. Although the oligomeric state of the M2 and E proteins are thought to be tetrameric and pentameric respectively, determining the oligomeric states of small transmembrane peptide complexes within membranes is challenging.

Native or non-denaturing mass spectrometry (MS) data suggests a more complex picture of the oligomeric state than previously assumed, highlighting the need for novel analytical methods to understand how these important biomedical targets interact within lipid membranes. This webinar will introduce the native MS and lipid nanodisc techniques and demonstrate how this can be used to directly measure the oligomeric state of protein and peptide complexes within intact model lipid bilayers. Ongoing studies on the M2 and E protein will be discussed.

Native Mass Spectrometry and COVID-19: Uncovering Drug Binding and Oligomerization

To confidently characterize complex lipidomes of whole organisms, researchers require comprehensive MS/MS coverage of detected lipids. Compared to conventional analyses, the timsTOF Pro, used with Parallel Accumulation Serial Fragmentation (PASEF) acquisition mode, acquires MS/MS spectra with uncompromised sensitivity and resolution.

This webinar will demonstrate Bruker’s fully integrated lipidomics workflow in MetaboScape and outline how novel 4D-lipidomics tools has been used to gain a better understanding of how a sphingolipid mutation in the C. elegans relates to an increased lifespan – or in other words, the fountain of youth.

4D-Lipidomics™: Searching for the Fountain of Youth

Mucosal barriers are the gateways to all internal organs, serving to transport oxygen, nutrients, and waste and at the same time performing enormous feats of protection against infection and other hazardous insults. The explosion of interest in the human microbiome – especially but not only that in the gut – has driven new interest in building human mucosal barrier models.

This talk will highlight three related themes: (i) engineering synthetic microenvironments to expand primary adult epithelial organoids and induce morphogenesis into mucosal barriers (ii) engineering microfluidic devices to create microbial-mucosal interfaces that enable chronic co-culture of the most super strict anaerobes, such as Faecalibacterium prausnitzii, with a colon mucosal barrier and (iii) interconnection of mucosal barriers with other tissues in systemic circuits to illuminate the role of gut-derived bacterial metabolites on function of other organ systems. Examples will emphasize how these approaches can be used to model chronic inflammatory diseases.

Engineering Mucosal Barriers: From Organoids to Organs-on-Chips

CAR T-cell therapies are emerging anti-cancer treatments, whereby the patient’s immune cells are engineered to express chimeric antigen receptors (CARs) on their surface. Wider adoption of this therapeutic modality would benefit from innovative technologies that can improve the characterization of raw material quality attributes (MQA) and final product quality attributes (PQA).

Here, we present the development of a sensitive proteomic method to characterize CAR T cells using SWATH™ technology. We evaluated key steps of the data acquisition, from separation to detection, to enhance the sensitivity by data dependent and independent methods.

The data represent an instrument benchmarking that will ultimately be used as performance qualification metrics to assure instrument control for biologically relevant decision making of CAR T proteomic samples.

Webinars by Technology Networks

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.